Immunocompatibility properties of lipid–polymer hybrid nanoparticles with heterogeneous surface functional groups
Open accessThe DOI matches its Crossref record.
Abstract
Here we report the immunological characterization of lipid-polymer hybrid nanoparticles (NPs) and propose a method to control the levels of complement activation induced by these NPs. This method consists of the highly specific modification of the NP surface with methoxyl, carboxyl, and amine groups. Hybrid NPs with methoxyl surface groups induced the lowest complement activation, whereas the NPs with amine surface groups induced the highest activation. All possible combinations among carboxyl, amine, and methoxyl groups also activated the complement system to a certain extent. All types of NPs activated the complement system primarily via the alternative pathway rather than the lectin pathway The classical pathway was activated to a very small extent by the NPs with carboxyl and amine surface groups. Human serum and plasma protein binding studies showed that these NPs had different protein binding patterns. Studies of both complement activation and coagulation activation suggested that NPs with methoxyl surface groups might be an ideal candidate for drug delivery applications, since they are not likely to cause any immunological adverse reaction in the human body.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Self-citationBertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Self-citationTargeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Self-citationHrkach, J., Von Hoff, D., Ali, M. M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003651 · Cited by 1,147
Self-citationBiocompatibility of engineered nanoparticles for drug delivery
Naahidi, S., Jafari, M., Edalat, F., Raymond, K., Khademhosseini, A., & Chen, P. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.12.013 · Cited by 809
Bertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., Lim, J.-M., Karnik, R., Langer, R., & Farokhzad, O. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00600-w · Cited by 708
Self-citationLipid–polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review
Hadinoto, K., Sundaresan, A., & Cheow, W. S. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.07.002 · Cited by 702
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060571 · Cited by 623
“It also changes the opsonization profile of the nanoparticle [61].”
BackgroundFactors Controlling Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective
Moghimi, S. M., Hunter, A. C., & Andresen, T. L. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134623 · Cited by 545
Moradi Kashkooli, F., Soltani, M., & Souri, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.012 · Cited by 514
Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine
Zhang, X.-Q., Xu, X., Bertrand, N., Pridgen, E., Swami, A., & Farokhzad, O. C. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.005 · Cited by 487
Self-citationCore–shell-type lipid–polymer hybrid nanoparticles as a drug delivery platform
Mandal, B., Bhattacharjee, H., Mittal, N., Sah, H., Balabathula, P., Thoma, L. A., & Wood, G. C. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2012.11.010 · Cited by 467
Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona
Blume, J. E., Manning, W. C., Troiano, G., Hornburg, D., Figa, M., Hesterberg, L., Platt, T. L., Zhao, X., Cuaresma, R. A., Everley, P. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17033-7 · Cited by 452
Self-citationNanotechnology for protein delivery: Overview and perspectives
Yu, M., Wu, J., Shi, J., & Farokhzad, O. C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.012 · Cited by 410
Self-citationNanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems
Guan, S., & Rosenecker, J. (2017) · Gene Therapy · doi:10.1038/gt.2017.5 · Cited by 389
Nanoparticle Technologies for Cancer Therapy
Alexis, F., Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_2 · Cited by 364
Self-citationKarmali, P. P., & Simberg, D. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.554818 · Cited by 361
Valencia, P. M., Basto, P. A., Zhang, L., Rhee, M., Langer, R., Farokhzad, O. C., & Karnik, R. (2010) · ACS Nano · doi:10.1021/nn901433u · Cited by 335
Self-citationPolymeric Nanoparticles for Delivery of Natural Bioactive Agents: Recent Advances and Challenges
Elmowafy, M., Shalaby, K., Elkomy, M. H., Alsaidan, O. A., Gomaa, H. A. M., Abdelgawad, M. A., & Mostafa, E. M. (2023) · Polymers · doi:10.3390/polym15051123 · Cited by 332
Evolution of macromolecular complexity in drug delivery systems
Kakkar, A., Traverso, G., Farokhzad, O. C., Weissleder, R., & Langer, R. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0063 · Cited by 320
Self-citationSivadasan, D., Sultan, M. H., Madkhali, O., Almoshari, Y., & Thangavel, N. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081291 · Cited by 288
Material properties in complement activation
Moghimi, S. M., Andersen, A. J., Ahmadvand, D., Wibroe, P. P., Andresen, T. L., & Hunter, A. C. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.002 · Cited by 268
Gajbhiye, K. R., Salve, R., Narwade, M., Sheikh, A., Kesharwani, P., & Gajbhiye, V. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01849-0 · Cited by 262
Biomaterials for mRNA delivery
Islam, M. A., Reesor, E. K. G., Xu, Y., Zope, H. R., Zetter, B. R., & Shi, J. (2015) · Biomaterials Science · doi:10.1039/c5bm00198f · Cited by 176
Padín-González, E., Lancaster, P., Bottini, M., Gasco, P., Tran, L., Fadeel, B., Wilkins, T., & Monopoli, M. P. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.882363 · Cited by 166
Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy
Mohanty, A., Uthaman, S., & Park, I.-K. (2020) · Molecules · doi:10.3390/molecules25194377 · Cited by 160
Kim, M., Shin, M., Zhao, Y., Ghosh, M., & Son, Y. (2024) · Small Science · doi:10.1002/smsc.202400280 · Cited by 97
Metadata
- Authors
- Salvador-Morales, C., Zhang, L., Langer, R., & Farokhzad, O. C.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2009-04
- Volume
- 30
- Issue
- 12
- Pages
- 2231-2240
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2144350652
- Cited by
- 250
- References
- 0
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.